Trial · NCT07888413
Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic Surgery
NCT07888413, Phase 4, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic Surgery. Trials, record NCT07888413. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07888413
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic Surgery
- NCT number
- NCT07888413
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 450 participants, estimated
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Conditions
- Chronic Pain, Postoperative
- Interventions
- Esketamine combined with dexmedetomidine, saline placebo
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Chronic Pain at 3 Months After Pancreatic Surgery | At 3 months after pancreatic surgery | The outcome measure reports the number and proportion of participants with chronic postsurgical pain (CPSP) at 3 months after pancreatic surgery. CPSP is assessed using the Chronic Postsurgical Pain (CPSP) Scale, a yes/no questionnaire. Participants are classified as having CPSP if they meet the following criteria: (1) pain lasting 3 months or longer after surgery; (2) pain is new after surgery or more painful than before surgery; (3) pain is localized to the surgical area; and (4) other causes of pain, such as local recurrence, infection, or metastasis, are excluded. The scale does not produce a numerical score. |
| Secondary | Cumulative Opioid Consumption Within 3 Days After Surgery | From the end of surgery to 3 days after surgery | Cumulative opioid consumption within 3 days after surgery is a continuous measure of the total amount of opioids administered during the first 3 postoperative days . It is assessed from patient-controlled intravenous analgesia (PCIA) pump records and nursing medication administration records. The PCIA pump records the total volume of analgesic solution used; because the sufentanil concentration in the PCIA solution is known (sufentanil 1.5 μg/kg in 100 mL in both groups), the cumulative sufentanil dose delivered via PCIA is calculated. Any additional opioid rescue analgesia administered during this period (e.g., intravenous sufentanil boluses) is also recorded and included. |
| Secondary | Sleep Quality on the First 3 Postoperative Nights | During the first 3 nights after surgery | Sleep quality during the first 3 postoperative nights is assessed on the mornings of postoperative days 1, 2, and 3 (8:00-10:00) for the previous night. Subjective sleep quality is measured using the Richards-Campbell Sleep Questionnaire (RCSQ) and a sleep Numeric Rating Scale (NRS). The RCSQ consists of 6 items, each scored on a 0-100 visual analogue scale, with higher scores indicating better sleep quality. The sleep NRS ranges from 0 to 10, where 0 indicates the best possible sleep quality and 10 indicates the worst possible sleep quality; therefore, higher NRS scores indicate worse sleep quality. |
| Secondary | Length of Postoperative Hospital Stay | From the day of surgery to hospital discharge | This outcome measure reports the length of postoperative hospital stay as a continuous variable, measured in days. It is defined as the number of days from the date of surgery to the date of hospital discharge, as documented in the hospital medical record. |
| Secondary | Incidence of Postoperative Complications, Including All-Cause Mortality, Within 30 Days After Surgery | Within 30 days after surgery | This outcome measure reports the incidence of participants who experience at least one postoperative complication, including all-cause mortality, within 30 days after pancreatic surgery. Pre-specified examples of complications include cardiac complications (myocardial injury or myocardial infarction, new-onset arrhythmia, acute heart failure, cardiac arrest), stroke, pulmonary complications (pneumonia, pulmonary aspiration, atelectasis, acute respiratory distress syndrome), acute renal insufficiency, gastrointestinal complications (gastrointestinal infarction, gastrointestinal bleeding, gastrointestinal perforation, intestinal obstruction), and unplanned readmission. |
| Secondary | Depression Score at 3 Months After Surgery | At 3 months after surgery | Depression at 3 months after surgery is assessed using the Patient Health Questionnaire-9 (PHQ-9) , a 9-item self-reported depression screening questionnaire. Each item is scored from 0 to 3, and the total PHQ-9 score ranges from 0 to 27. A higher total score indicates more severe depressive symptoms. |
| Secondary | EORTC QLQ-PAN26 Score at 3 Months After Surgery | At 3 months after surgery | The outcome measure reports the EORTC QLQ-PAN26 score at 3 months after surgery. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Pancreatic Cancer Module 26 (EORTC QLQ-PAN26) is a 26-item, pancreatic cancer-specific, patient-reported quality-of-life questionnaire module. Each item is rated on a 4-point Likert scale (1 = Not at all, 2 = A little, 3 = Somewhat, 4 = Very much).For symptom items, higher scores indicate more severe symptoms. For functional items, higher scores indicate better quality of life. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07888413
GET https://conductscience.org/api/trials/v1/NCT07888413/registered